Cargando…
Epigenetics of renal cell carcinoma: the path towards new diagnostics and therapeutics
Aberrant DNA methylation, in particular promoter hypermethylation and transcriptional silencing of tumor suppressor genes, has an important role in the development of many human cancers, including renal cell carcinoma (RCC). Indeed, apart from mutations in the well studied von Hippel-Lindau gene (VH...
Autores principales: | , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3092110/ https://www.ncbi.nlm.nih.gov/pubmed/20815920 http://dx.doi.org/10.1186/gm180 |
_version_ | 1782203354812776448 |
---|---|
author | Morris, Mark R Maher, Eamonn R |
author_facet | Morris, Mark R Maher, Eamonn R |
author_sort | Morris, Mark R |
collection | PubMed |
description | Aberrant DNA methylation, in particular promoter hypermethylation and transcriptional silencing of tumor suppressor genes, has an important role in the development of many human cancers, including renal cell carcinoma (RCC). Indeed, apart from mutations in the well studied von Hippel-Lindau gene (VHL), the mutation frequency rates of known tumor suppressor genes in RCC are generally low, but the number of genes found to show frequent inactivation by promoter methylation in RCC continues to grow. Here, we review the genes identified as epigenetically silenced in RCC and their relationship to pathways of tumor development. Increased understanding of RCC epigenetics provides new insights into the molecular pathogenesis of RCC and opportunities for developing novel strategies for the diagnosis, prognosis and management of RCC. |
format | Text |
id | pubmed-3092110 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2010 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-30921102011-09-03 Epigenetics of renal cell carcinoma: the path towards new diagnostics and therapeutics Morris, Mark R Maher, Eamonn R Genome Med Review Aberrant DNA methylation, in particular promoter hypermethylation and transcriptional silencing of tumor suppressor genes, has an important role in the development of many human cancers, including renal cell carcinoma (RCC). Indeed, apart from mutations in the well studied von Hippel-Lindau gene (VHL), the mutation frequency rates of known tumor suppressor genes in RCC are generally low, but the number of genes found to show frequent inactivation by promoter methylation in RCC continues to grow. Here, we review the genes identified as epigenetically silenced in RCC and their relationship to pathways of tumor development. Increased understanding of RCC epigenetics provides new insights into the molecular pathogenesis of RCC and opportunities for developing novel strategies for the diagnosis, prognosis and management of RCC. BioMed Central 2010-09-03 /pmc/articles/PMC3092110/ /pubmed/20815920 http://dx.doi.org/10.1186/gm180 Text en Copyright ©2010 BioMed Central Ltd. |
spellingShingle | Review Morris, Mark R Maher, Eamonn R Epigenetics of renal cell carcinoma: the path towards new diagnostics and therapeutics |
title | Epigenetics of renal cell carcinoma: the path towards new diagnostics and therapeutics |
title_full | Epigenetics of renal cell carcinoma: the path towards new diagnostics and therapeutics |
title_fullStr | Epigenetics of renal cell carcinoma: the path towards new diagnostics and therapeutics |
title_full_unstemmed | Epigenetics of renal cell carcinoma: the path towards new diagnostics and therapeutics |
title_short | Epigenetics of renal cell carcinoma: the path towards new diagnostics and therapeutics |
title_sort | epigenetics of renal cell carcinoma: the path towards new diagnostics and therapeutics |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3092110/ https://www.ncbi.nlm.nih.gov/pubmed/20815920 http://dx.doi.org/10.1186/gm180 |
work_keys_str_mv | AT morrismarkr epigeneticsofrenalcellcarcinomathepathtowardsnewdiagnosticsandtherapeutics AT mahereamonnr epigeneticsofrenalcellcarcinomathepathtowardsnewdiagnosticsandtherapeutics |